default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

China OKs Alteogen’s Herceptin biosimilar for clinical trials

Lee Han-soo  Published 2019.07.04  14:04  Updated 2019.07.04 14:04

공유
default_news_ad2

Alteogen said that Qilu Pharmaceutical, its Chinese partner, has received investigational new drug (IND) approval for ALT-02, a Herceptin biosimilar, from the China Food and Drug Administration.

The Korean company licensed out the substance to Qilu in 2017, giving the latter exclusive rights in China, Hong Kong, and Macau.

With the Chinese approval, Alteogen has received its third milestone payment and will also get additional milestones if Qilu completes clinical trials and commercializes the product. The company will receive royalties for 10 years from the product's launch.

Alteogen said it could not disclose the amount of the milestone because of a confidentiality request from Qilu.

“Clinical approval of our Herceptin biosimilar in China can give us a competitive edge in the giant market,” the company said in a news release. “As Qilu plans to launch its phase 3 clinical trials on about 600 patients, we expect that the clinical trial will help us enter the European market.”

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch